Comparing the current results to its competitors, Zura Bio Limited reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.04 %, recorded in the same quarter.
Zura Bio Limited's Comment on Competition and Industry Peers
The company is evaluating the competitive landscape for its products crebankitug and torudokimab, with a focus on developments in IL-7, TSLP, IL-33, and ST2-targeted programs. This assessment includes potential therapeutic indications, disease selection, clinical trial design, and the timing and scope of future clinical studies. The company does not own or operate manufacturing facilities and depends on contract manufacturers for the production of drug substances and finished products.
July 18, 2025
In the fast-paced world of biotech, Zura Bio Limited (Nasdaq: ZURA), a clinical-stage company specializing in multi-asset immunology and the development of novel dual-pathway antibodies, has made noteworthy strides in its recent corporate developments. As the company continues its pursuit of innovative solutions for autoimmune and inflammatory diseases, it concurrently addresses critical workforce expansions through strategic inducement grants. Inducement Grants as a Strategic Initiative On July 15, 2025, Zura Bio announced the issuance of inducement awards, including options to acquire up to 890,950 Class A Ordinary Shares. This allocation was extended to seven newly hired employees, featuring a significant...
November 14, 2024
In a pivotal move for the clinical-stage immunology field, Zura Bio Limited (Nasdaq: ZURA) has announced the submission of a protocol for a Phase 2 study of tibulizumab to the U.S. Food and Drug Administration (FDA). Tibulizumab is a cutting-edge humanized tetravalent bispecific dual antagonist antibody, which uniquely neutralizes both IL-17A and another yet-to-be-disclosed pathway, aiming to address the significant unmet medical needs in patients with systemic sclerosis.Systemic sclerosis, also known as scleroderma, is an autoimmune disease characterized by the hardening and tightening of the skin and connective tissues, leading to debilitating symptoms and complications. The Phase 2 study aims to evaluate ...
August 11, 2024
HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), a leading clinical-stage immunology company specializing in the development of innovative dual-pathway antibodies for the treatment of autoimmune and inflammatory diseases, has announced the expiration and results of its previously proposed exchange offer (the Exchange Offer) and consent solicitation (the Consent Solicitation) regarding its outstanding public warrants that were issued in connection with its initial public offering (IPO). The Exchange Offer and Consent Solicitation were designed to facilitate a direct engagement with investors and stakeholders regarding Zura Bio’s warrants that allow for the purchase of shares of its common stock. This stra...
June 14, 2024
HENDERSON, Nev. Zura Bio Limited (Nasdaq: ZURA), an emergent force in the immunology field, has taken a significant stride forward with the release of encouraging data from its Phase 1 study of tibulizumab (ZB-106) at the Annual European Congress of Rheumatology (EULAR) 2024. This clinical-stage company is distinguished by its innovative approach to developing dual-pathway antibodies aiming to tackle complex autoimmune and inflammatory diseases. Breakthrough Phase 1 Data for Sjogren s Syndrome Tibulizumab, Zura Bio’s pioneering monoclonal antibody, was evaluated in a Phase 1 trial to assess its safety, tolerability, and preliminary efficacy in patients suffering from Sjogren s syndrome a chronic autoim...
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Arcellx Inc operates on a business model focused on developing and commercializing next-generation cell therapies for the treatment of various diseases by utilizing its proprietary ARC-SparX platform technology. The company intends to leverage its technology to create novel and improved therapies, targeting both liquid and solid tumors, aiming for better patient outcomes.
Sources:
Zura Bio Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zura Bio Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
